REFERENCES:
[1] Barrett, J.S., Bishai, R., Bucci‐Rechtweg, C., Cheung, A., Corriol‐Rohou, S., Haertter, S., James, A., Kovacs, S.J., Liu, J., Potempa, D., Strougo, A., Vanevski, K. and (2018), Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation. Clin. Pharmacol. Ther., 103: 419-433. doi:10.1002/cpt.1000
[2] Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19, The Pediatric Infectious Disease Journal: May 2020. 39(5): 355-368. doi: 10.1097/INF.0000000000002660
[3] Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry. Journal of Virology 85(2): 873–882, 2011, doi:10.1128/JVI.02062-10.
[4] Hoffmann M et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. 2020, Cell 181(2): 271–280, https://doi.org/10.1016/j.cell.2020.02.052.
[5] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
[6] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199-207.
[7] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
[8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
[9] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
[10] Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
[11] Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
[12] Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020.
[13] Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088‐1095. doi:10.1111/apa.15270
[14] Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
[15] Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, Li P, Zhou Y, Lin YF, Duan Q, Luo G, Fan S, Lu Y, Feng A, Zhan Y, Liang B, Cai W, Zhang L, Du X, Li L, Shu Y, Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020 Jun;80(6):656-665. doi: 10.1016/j.jinf.2020.03.041. Epub 2020 Apr 10. PMID: 32283155; PMCID: PMC7151416.
[16] Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020 Mar 16;10:40. doi: 10.1186/s13578-020-00404-4. PMID: 32190290; PMCID: PMC7074995.
[17] Hasan A, Mehmood N, Fergie J (March 31, 2020) Coronavirus Disease (COVID-19) and Pediatric Patients: A Review of Epidemiology, Symptomatology, Laboratory and Imaging Results to Guide the Development of a Management Algorithm. Cureus 12(3): e7485. doi:10.7759/cureus.7485
[18] Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405‐407, doi:10.1016/j.healun.2020.03.012
[19] Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016 Mar-Apr;27(2):89-94. doi: 10.5830/CVJA-2016-021. PMID: 27213856; PMCID: PMC4928162.
[20] Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015 Nov;39(7):512-9. doi: 10.1053/j.semperi.2015.08.003. PMID: 26452316; PMCID: PMC4809631.
[21] Guidance for Industry: Pediatric Information Incorporated into Human Prescription Drug and Biological Product Labeling. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2019, https://www.fda.gov/media/84949/download
[22] Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), December 2014, https://www.fda.gov/media/90358/download
[23] Draft guidance for industry: How to comply with the Pediatric Research Equity Act. Silver Spring, MD: Food and Drug Administration; 2005. [(accessed July 9, 2020)]. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077855.pdf
[24] Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M and Mayhew S. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery 19, 305-306 (2020), doi: 10.1038/d41573-020-00073-5
[25] Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, Kumar D, Ramakrishnan MA, Malik YS, Singh R, Malik SVS, Singh RK, Chaicumpa W. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Front Immunol. 2018 Aug 10;9:1803. doi: 10.3389/fimmu.2018.01803. PMID: 30147687; PMCID: PMC6095993.
[26] Draft landscape of COVID 19 candidate vaccines. World Health Organization. 18 June 2020. Archived from the original on 14 May 2020. Updated July 7, 2020 Retrieved 9 July 2020, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[27] Gomes MF, de la Fuente-Núñez V, Saxena A, Kuesel AC. Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reprod Health. 2017 Dec 14;14(Suppl 3):172. doi: 10.1186/s12978-017-0430-2. PMID: 29297366; PMCID: PMC5751665.
[28] Guidance for Industry: Post-approval Pregnancy Safety Studies. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2019, https://www.fda.gov/media/124746/download
[29] Institute of Medicine. 2012. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press. https://doi.org/10.17226/13164.
[30] Check Hayden, E. Vaccines given a clean bill of health. Nature (2011). https://doi.org/10.1038/news.2011.505
[31] Faucette AN, Pawlitz MD, Pei B, Yao F, Chen K. Immunization of pregnant women: Future of early infant protection. Hum Vaccin Immunother. 2015;11(11):2549-55. doi: 10.1080/21645515.2015.1070984. Epub 2015 Sep 14. PMID: 26366844; PMCID: PMC4685701.
[32] Vivanti, A.J., Vauloup-Fellous, C., Prevot, S. et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun 11, 3572 (2020). https://doi.org/10.1038/s41467-020-17436-6.
[33] Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020;383:347-358.
[34] Callaway, E. (2020c). Coronavirus vaccine trials have delivered their first results - but their promise is still unclear. Nature 581, 363–364. doi: 10.1038/d41586-020-01092-3
[35] Cristiani L, Mancino E, Matera L, et al. Will children reveal their secret? The coronavirus dilemma. Eur Respir J. 2020;55(4):2000749. Published 2020 Apr 23. doi:10.1183/13993003.00749-2020
[36] Park YJ, Choe YJ, Park O, Park SY, Kim YM, Kim J, et al. Contact tracing during coronavirus disease outbreak, South Korea, 2020. Emerg Infect Dis. 2020 Oct [date cited]. https://doi.org/10.3201/eid2610.201315, DOI: 10.3201/eid2610.201315
[37] Shiau S, Kuhn L. Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby. Expert Rev Anti Infect Ther. 2014 Mar;12(3):307-18. doi: 10.1586/14787210.2014.888311. Epub 2014 Feb 9. PMID: 24506199; PMCID: PMC5389381.
[38] Siemieniuk Reed A C, Lytvyn Lyubov, Mah Ming Jinell, Mullen Rhonda Marama, Anam Florence, Otieno Teresia et al. Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline BMJ 2017; 358 :j3961.
[39] Coutre L. Cleveland Clinic, Epic develop home monitoring tool for COVID-19 patients. April 30, 2020. Modern Healthcare. https://www.modernhealthcare.com/technology/cleveland-clinic-epic-develop-home-monitoring-tool-covid-19-patients.
[40] Boissy A. Getting to Patient-Centered Care in a Post–Covid-19 Digital World: A Proposal for Novel Surveys, Methodology, and Patient Experience Maturity Assessment. NEJM Catalyst Innovations in Care Delivery Vol. 1, No. 4: 1-26, 2020.
[41] COVID-19 Prevention Trials Network (COVPN), https://www.coronaviruspreventionnetwork.org/, last accessed 7/27, 2020.
[42] HIV Vaccine Trials Network (HVTN), https://www.hvtn.org/en.html, last accessed 7/27, 2020.
[43] HIV Prevention Trials Network (HPTN), https://www.hptn.org/, last accessed 7/27, 2020.
[44] Infectious Diseases Clinical Research Consortium (IDCRC), https://www.niaid.nih.gov/research/idcrc, last accessed 7/27, 2020.
[45] Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study [published online ahead of print, 2020 Apr 27]. Lancet Infect Dis. 2020; S1473-3099(20)30287-5. doi:10.1016/S1473-3099(20)30287-5
[46] Lauer, Stephen A., Grantz, Kyra H., Bi, Qifang, Jones, Forrest K., Zheng, Qulu, Meredith, Hannah R., Azman, Andrew S., Reich, Nicholas G., Lessler, Justin. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine 2020 172:9, 577-582.
[47] Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
[48] Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. Published online May 11, 2020. doi:10.1001/jamapediatrics.2020.1948
[49] CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:422.
[50] Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility – King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020; 69:377–81.
[51] Smith ER, Klein-Schwartz W. Are 1–2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. The Journal of Emergency Medicine 28(4): 437-443, 2005.
[52] McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12(5):388-396. doi:10.1016/S1473-3099(11)70339-5.
[53] Anna-Liisa Laaksonen, Veli Koskiahde & Kale Juva (1974) Dosage of Antimalarial Drugs for Children with Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Clinical Study with Determination of Serum Concentrations of Chloroquine and Hydroxychloroquine, Scandinavian Journal of Rheumatology, 3:2, 103-108, DOI: 10.3109/03009747409115809
[54] Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76-82. doi:10.1161/CIRCULATIONAHA.111.089268.
[55] Bouazza N, Treluyer JM, Foissac F, et al. Favipiravir for children with Ebola. Lancet. 2015;385(9968):603-604. doi:10.1016/S0140-6736(15)60232-X.
[56] Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79-81. doi:10.1017/dmp.2014.151.
[57] Rudin C, Burri M, Shen Y, et al. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J. 2008;27(5):431-437. doi:10.1097 / INF.0b013e3181646d5a.
[58] Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008 Oct;4(5):1023-33. doi: 10.2147/tcrm.s3285. PMID: 19209283; PMCID: PMC2621403.
[59] Simon A, Warszawski J, Kariyawasam D, et al. Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected Mothers. JAMA. 2011;306(1):70–78. doi:10.1001/jama.2011.915
[60] Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009;51(4):456-461. doi:10.1097/QAI.0b013e3181a2813f
[61] Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005;41(5):1013-1018. doi:10.1002/hep.20661
[62] Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, McWilliams BC, Lauer BA. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. Journal of Pediatrics (1990) 117(5): 792-798.
[63] American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics. 1993;92(3):501-504.
[64] Schlossberg D, Samuel R. YOMESAN (Niclosamide) in “Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition” (2017) Wiley Online Library, https://doi.org/10.1002/9781119220787.ch199, p 432.
[65] Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360(9343):1375-1380. doi:10.1016/S0140-6736(02)11401-2.
[66] Asami T, Tomisawa S, Uchiyama M. Effect of oral camostat mesilate on hematuria and/or proteinuria in children. Pediatr Nephrol. 2004;19(3):313-316. doi:10.1007/s00467-003-1377-9.
[67] Svenningsen P, Andersen H, Nielsen LH, Jensen BL. Urinary serine proteases and activation of ENaC in kidney–implications for physiological renal salt handling and hypertensive disorders with albuminuria. Pflugers Arch. 2015;467(3):531-542. doi:10.1007/s00424-014-1661-5.
[68] Lee, Sang & Cho, Heeyeon. (2014). The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding. Journal of the Korean Society of Pediatric Nephrology. 18. 98. 10.3339/jkspn.2014.18.2.98.
[69] Hara T, Kanasaki H, Oride A, Ishihara T, Kyo S. A Case of Idiopathic Acute Pancreatitis in the First Trimester of Pregnancy. Case Rep Obstet Gynecol. 2015; 2015:469527. doi: 10.1155/2015/469527. Epub 2015 Dec 30. PMID: 26843995; PMCID: PMC4710924.
[70] Wu KH, Weng T, Wu HP, Peng CT, Sheu JN, Chao YH. Effective treatment of severe BK virus-associated hemorrhagic cystitis with leflunomide in children after hematopoietic stem cell transplantation: a pilot study. Pediatr Infect Dis J. 2014;33(11):1193-1195. doi:10.1097/INF.0000000000000407
[71] Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012; 35: 501–515.
[72] Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494-1503. doi:10.1002/art.27358.
[73] Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34(7):991-1001. doi:10.1086/338814.
[74] Aronson JK. Teicoplanin, In “Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions,” 2016, Elsevier Publishers, p 714-720.
[75] Giardina AC, Ehlers KH, Morrison JB, Engle MA. Serum digitoxin concentrations in infants and children. Circulation. 1975;51(4):713-717. doi:10.1161/01.cir.51.4.713.
[76] Okita, G.T., Plotz, E.J., Davis, M.E.: Placental transfer of radioactive digitoxin in pregnant women and its fetal distribution. Circulation 9, 376–380 (1956).
[77] Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag. 2009;5(3):595-615. doi:10.2147/tcrm.s4595.
[78] Zorrilla CD, Wright R, Oisyemi OO, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunvair/ritonavir 600/100 mg administered twice daily. HIV Med. 2014;15(1):50–56.
[79] Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978-984. doi:10.1016/s0140-6736(02)11081-6.
[80] Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001; 184:1352–6.
[81] del Mar Saez-De-Ocariz M., McKinster C.D., Orozco-Covarrubias L., Tamayo-Sánchez L., Ruiz-Maldonaldo R. (2002) Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin. Clin. Exp. Dermatol. 27, 264–267.
[82] Richard-Lenoble D, Chandeniera J, Gaxotte P. Ivermectin and filariasis. Fundamental & Clinical Pharmacology 17 (2003) 199–203.
[84] Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020 May 12;14(4):641-648. doi: 10.1016/j.dsx.2020.05.018. Epub ahead of print. PMID: 32428865; PMCID: PMC7214279.
[83] FDA emergency use authorization for remdisivir. https://www.fda.gov/media/137564/download (Accessed May 5, 2020)
[85] Wilson K.C., Chotirmall S.H., Bai C., Rello J. COVID-19: interim guidance on management pending empirical evidence. https://www.thoracic.org/covid/covid-19-guidance.pdf April 3. 2020.
[86] Webb NJ, Lam C, Loeys T, et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol. 2010;5(3):417-424. doi:10.2215/CJN.06620909.
[87] Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet. 2001;357(9253):363. doi:10.1016/S0140-6736(00)03648-5.
[88] Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28(3):231-238. doi:10.1385/CRIAI:28:3:231.
[89] Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016;46(2):238-245. doi:10.1016/j.semarthrit.2016.05.004.
[90] Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114(5):988-995. doi:10.1016/s0016-5085(98)70318-x.
[91] Séror J, Sentilhes L, Lefebvre-Lacoeuille C, Marpeau L. Interferon-alpha for treatment of essential thrombocythemia during pregnancy: case report and review of the literature. Fetal Diagn Ther. 2009;25(1):136-140. doi:10.1159/000207555.
[92] Smith RL. Pediatric psoriasis treated with apremilast. JAAD Case Rep. 2016 Feb 27;2(1):89-91. doi: 10.1016/j.jdcr.2015.12.005. PMID: 27051839; PMCID: PMC4809471.
[93] Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389-397. doi:10.1016/j.jaad.2019.08.019